LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

LLY

776.45

-2.39%↓

JNJ

152.33

+0.12%↑

ABBV

182.26

-2.5%↓

NVO

68.53

+1.17%↑

UNH

308.74

+2.11%↑

Search

Bridgebio Pharma Inc

Fechado

SetorSaúde

44.85 0.09

Visão Geral

Variação de preço das ações

24h

Atual

Mín

44.1

Máximo

45.47

Indicadores-chave

By Trading Economics

Rendimento

100M

-167M

Vendas

111M

117M

EPS

-0.989

Margem de lucro

-143.546

Funcionários

725

EBITDA

109M

-126M

Recomendações

By TipRanks

Recomendações

Compra Forte

Previsão para 12 meses

+34.24% upside

Dividendos

By Dow Jones

Próximos Ganhos

31 de jul. de 2025

Estatísticas de Mercado

By TradingEconomics

Capitalização de Mercado

1.2B

8B

Abertura anterior

44.76

Fecho anterior

44.85

Sentimento de Notícias

By Acuity

26%

74%

56 / 380 Ranking em Healthcare

Pontuação Técnica

By Trading Central

Confiança

Strong Bearish Evidence

Bridgebio Pharma Inc Gráfico

O desempenho passado não é um indicador confiável de resultados futuros.

Notícias Relacionadas

11 de abr. de 2025, 09:30 UTC

Principais Notícias

How to Play the Biotech Meltdown in the Age of RFK Jr. and Tariffs -- Heard on the Street -- WSJ

12 de set. de 2024, 17:01 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- Update

12 de set. de 2024, 11:00 UTC

Principais Notícias

The Brawl Taking Shape Over Pfizer's Multibillion-Dollar Heart Monopoly -- Heard on the Street -- WSJ

Comparação entre Pares

Variação de preço

Bridgebio Pharma Inc Previsão

Preço-alvo

By TipRanks

34.24% parte superior

Previsão para 12 meses

Média 60.57 USD  34.24%

Máximo 95 USD

Mínimo 42 USD

Com base em 16 analistas de Wall Street que oferecem metas de preço de 12 meses para Bridgebio Pharma Inc - Dist nos últimos 3 meses.

Consenso de Avaliação

By TipRanks

Compra Forte

16 ratings

15

Comprar

1

Manter

0

Vender

Pontuação Técnica

By Trading Central

34.71 / 36.9Suporte e Resistência

Curto Prazo

Strong Bearish Evidence

Médio Prazo

Strong Bullish Evidence

Longo Prazo

Bullish Evidence

Sentimento

By Acuity

56 / 380 Ranking em Saúde

Sentimento de Notícias

Evidência de Tendência de Alta

Volatilidade

Abaixo da média

Volume de Notícias (RCV)

Abaixo da média

Informação Financeira

Custos administrativos e de venda

Custos Operacionais

Lucro antes de imposto

Vendas

Custo das vendas

Lucro bruto sobre vendas

Despesa com juros da dívida

EBITDA

Resultado Operacional

$

Sobre Bridgebio Pharma Inc

BridgeBio Pharma, Inc., a commercial-stage biopharmaceutical company, discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases and cancers. Its products in development programs include AG10, a next-generation oral small molecule near-complete TTR stabilizer that is in Phase 3 clinical trial for the treatment of TTR amyloidosis, or transthyretin amyloid cardiomyopathy (ATTR-CM); low-dose infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor, which is in Phase 3 double-blinded, placebo-controlled pivotal study for the treatment option for children with achondroplasia; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 1/2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD. The company also develops Encaleret, a small molecule antagonist of the calcium sensing receptor, or CaSR, which is in phase 3 clinical trial for treating autosomal dominant hypocalcemia type 1, or ADH1; and BBP-418, a glycosylation substrate pro-drug that is in Phase 3 clinical trial for treating limb-girdle muscular dystrophy type 2I/R9 (LGMD2I/R9). In addition, it engages in developing products for mendelian, oncology, and gene therapy diseases. BridgeBio Pharma, Inc. has license and collaboration agreements with the Leland Stanford Junior University; and Leidos Biomedical Research, Inc. The company was founded in 2015 and is headquartered in Palo Alto, California.